UTR Therapeutics Publishes Landmark Preclinical Data in Frontiers in Pharmacology Supporting IND Submission for First-in-Class c-MYC RNA TherapeuticNEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- UTR Therapeutics Inc., a biotechnology company advancing a novel RNA Overwriting platform, today announced the peer-reviewed publication of preclinical data in Frontiers in Pharmacology demonstrating compelling efficacy of its lead candidate UTRxM1-18 in aggressive pancreatic cancer models. These findings are part of the company’s Investigational New Drug (IND) submission to the U.S. Food and Drug Administration, filed in May 2025.
UTR Therapeutics Inc Announces IND submission to the US FDA for a First-in-Human Clinical Trial of an mRNA destabilizing drug targeting c-MYC driven cancersNEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- UTR Therapeutics Inc (UTRx Inc.), a drug development biotech company based in New York City, USA is pleased to announce a new milestone, the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for UTRxM1-18, a novel therapeutic approach for targeting c-MYC driven cancers. This milestone, driven by our innovative platform 3’UTR engineering technology, precisely targets specific transcripts and degrades them. This technology supports our vision of changing how we treat and live beyond cancer.
